Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa(Osaka Red Cross Hospital), Katsuyuki Hotta(Okayama University Hospital), Ernest Nadal(Institut d'Investigació Biomédica de Bellvitge), Toshiaki Takahashi(Okayama University), Stefan Hammerschmidt, Domenico Galetta(Istituto Tumori Bari), Bente Frimodt‐Moller(Heidelberg University), Jean-Louis Pujol(GlaxoSmithKline (Italy)), Keunchil Park(The University of Texas MD Anderson Cancer Center), Jcm Ho(Queen Mary Hospital), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Sotaro Enatsu(Eli Lilly (Japan)), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Alexis B. Cortot(Centre National de la Recherche Scientifique), Elizabeth Fabre(Assistance Publique – Hôpitaux de Paris), Jens Kollmeier(Helios Klinikum Emil von Behring), Fumio Imamura(Osaka International Cancer Institute), Jin‐Yuan Shih(National Taiwan University Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Kiyotaka Yoh(National Cancer Center Hospital East), Helge Bischoff(Heidelberg University), Edward B. Garon(University of California, Los Angeles), Martin Reck(German Center for Lung Research), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Chao‐Hua Chiu(Taipei Veterans General Hospital), Carla Visseren‐Grul(Aarhus University Hospital), Makoto Nishio(Japanese Foundation For Cancer Research), Walburga Engel-Riedel, Quincy S. Chu, Alessandro Del Conte(University of Catania), Kwok‐Hung Au(Queen Elizabeth Hospital), Giulia Pasello(University of Padua), Toru Kumagai(University of Pennsylvania), Corinne Lamour, Konstantinos Syrigos(National and Kapodistrian University of Athens), Wolfgang Schütte(Martha-Maria Hospital), Santiago Ponce Aix(Research Institute Hospital 12 de Octubre), Kwok Hung Au(Queen Elizabeth Hospital), Martin Kimmich(German Center for Lung Research), Annamaria H. Zimmermann(St Bartholomew's Hospital), Silvia Novello(University of Turin)
Cited by 617
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k